ACTU logo

ACTUATE THERAPEUTICS INC

ACTUNASDAQ
🏆 #4811 by market capUS Equity
$584.27▼ $11.98 (−2.05%)
Simulated price
🔔
Track ACTU
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 2.0%
7d—
14d—
30d—
ytd—
1y—
🏦Market Cap
$18M
Small Cap
📈Revenue Growth (YoY)
+0.0%
Slowing
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
52
Weak
No chart data available for ACTU.

Trading Snapshot

Day Range
$577.92 – $588.89
52-Week Range
$0.60 – $8.49
Volume
$5.46B
Avg Volume
$5.03B
Shares Outstanding
23.9M
Next Earnings
Nov 6, 2026

Fundamentals Snapshot

Annual Revenue
$3M
Last Q Revenue
$758,252
P/E Ratio
-0.8
P/S Ratio
0.0x
EPS (TTM)
$-0.86
Dividend Yield
0.00%
Dilution (1yr)
+19.1%

Why Investors Own ACTU

  • ✓High-growth profile — revenue up +13.5% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 45% gross margin and 28% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

ACTU logo

ACTUATE THERAPEUTICS INC

ACTU
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$22M▼ −10.6% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$19M▼ −12.1% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
23.2M▲ +19.1% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$13M▲ +$4M YoY
StockOtter · stockotter.space

About ACTUATE THERAPEUTICS INC

Actuate Therapeutics, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating treatments for various cancers. Its primary drug candidate is Elraglusib Injection, an innovative glycogen synthase kinase-3 (GSK-3) inhibitor designed to combat metastatic pancreatic ductal adenocarcinoma. Furthermore, Elraglusib is being developed to address other malignancies, including Ewing sarcoma, metastatic melanoma, and colorectal cancer. Originally named Apotheca Therapeutics, Inc., the organization rebranded as Actuate Therapeutics, Inc. in October 2015. Established in 2015, the company maintains its headquarters in Fort Worth, Texas.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Weak
52/100

Analyst Price Target

ⓘ
Average Target
$602.94
▲ +3.2% Upside
High Target$703.03
Low Target$500.16
Based on 11 analysts

Latest News & Updates

🚀
CNBC·2h ago

ACTUATE THERAPEUTICS INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Bloomberg·5h ago

Analysts lift ACTU price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
MarketWatch·1d ago

ACTUATE THERAPEUTICS INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.